SI-BONE, Inc.

Equities

SIBN

US8257041090

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-24 pm EDT			5-day change	1st Jan Change
13.55 ^USD	+1.04%		-9.18%	-35.45%

May. 14	Transcript : SI-BONE, Inc. Presents at Bank of America Health Care Conference 2024, May-14-2024 11:20 AM
May. 07	Morgan Stanley Trims Price Target on SI-Bone to $25 From $26, Keeps Overweight Rating	MT

SI-BONE, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024

May 06, 2024 at 04:10 pm EDT

SI-BONE, Inc. reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported sales was USD 37.87 million compared to USD 32.71 million a year ago. Net loss was USD 10.9 million compared to USD 11.13 million a year ago.

Basic loss per share from continuing operations was USD 0.27 compared to USD 0.32 a year ago. Diluted loss per share from continuing operations was USD 0.27 compared to USD 0.32 a year ago.

Latest news about SI-BONE, Inc.

Transcript : SI-BONE, Inc. Presents at Bank of America Health Care Conference 2024, May-14-2024 11:20 AM	May. 14
Morgan Stanley Trims Price Target on SI-Bone to $25 From $26, Keeps Overweight Rating	May. 07	MT
Transcript : SI-BONE, Inc., Q1 2024 Earnings Call, May 06, 2024	May. 06
Earnings Flash (SIBN) SI-BONE Posts Q1 Revenue $37.9M, vs. Street Est of $36.5M	May. 06	MT
SI-BONE, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 06	CI
Si-Bone, Inc. Increases Revenue Guidance for 2024	May. 06	CI
Piper Sandler Initiates SI-Bone With Overweight Rating, Price Target is $25	Mar. 28	MT
Transcript : SI-BONE, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 08:30 AM	Mar. 12
Morgan Stanley Raises SI-Bone Price Target to $26 From $25, Maintains Overweight Rating	Feb. 27	MT
Truist Securities Adjusts SI-Bone Price Target to $24 From $26, Maintains Buy Rating	Feb. 27	MT
Transcript : SI-BONE, Inc., Q4 2023 Earnings Call, Feb 26, 2024	Feb. 26
Earnings Flash (SIBN) SI-BONE Posts Q4 Revenue $38.9M, vs. Street Est of $38.6M	Feb. 26	MT
SI-BONE, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 26	CI
SI-BONE, Inc. Provides Earnings Guidance for the Year 2024	Feb. 26	CI
Si-bone Insider Sold Shares Worth $808,591, According to a Recent SEC Filing	Feb. 21	MT
SI-Bone Implant Receives Expanded FDA Approval	Jan. 30	MT
SI-Bone Shares Up After Receiving FDA Approval for Expanded Device Use	Jan. 30	DJ
SI-BONE, Inc. Receives FDA 510(k) Clearance for a Smaller Diameter iFuse Bedrock Granite Implant with an Expanded Indication and Application	Jan. 30	CI
SI-Bone, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year 2023	Jan. 08	CI
Truist Securities Adjusts Price Target on SI-Bone to $26 From $25, Maintains Buy Rating	Dec. 22	MT
Truist Securities Raises SI-Bone Price Target to $25 From $22, Maintains Buy Rating	Dec. 12	MT
Cantor Fitzgerald Adjusts SI-Bone's Price Target to $25 From $30, Maintains Overweight Rating	Nov. 07	MT
Morgan Stanley Adjusts Price Target on SI-Bone to $25 From $30, Maintains Overweight Rating	Nov. 07	MT
Needham Adjusts Price Target on SI-Bone to $25 From $32, Maintains Buy Rating	Nov. 07	MT
Transcript : SI-BONE, Inc., Q3 2023 Earnings Call, Nov 06, 2023	Nov. 06

Chart SI-BONE, Inc.

Duration

Period

More charts

Company Profile

SI-BONE, Inc. is a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy. The Company specializes in minimally invasive surgical implant systems to address sacroiliac joint dysfunction as well as address unmet clinical needs in pelvic fixation and management of pelvic fractures. The Company's products include a series of patented titanium implants and the instruments used to implant them, as well as implantable bone products. Its products include iFuse, iFuse-3D, iFuse-TORQ and iFuse Bedrock Granite. Within the United States, iFuse, iFuse-3D and iFuse-TORQ have clearances for applications across sacroiliac joint dysfunction and fusion, adult spinal deformity and degeneration, and pelvic trauma. Its first-generation iFuse, a machined triangular titanium implant, has a triangular cross section that resists twisting or rotation of the implant. The Company's second generation iFuse product, the iFuse-3D implant, is a patented titanium implant.

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-06-25 - Annual General Meeting

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for SI-BONE, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

13.55 USD

Average target price

25.56 USD

Spread / Average Target

+88.60%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Medical Equipment

	1st Jan change	Capi.
SI-BONE, INC.	-35.45%	558M
SHOCKWAVE MEDICAL, INC.	+75.35%	12.55B
PENUMBRA, INC.	-23.01%	7.51B
MASIMO CORPORATION	+8.35%	6.74B
JIANGSU YUYUE MEDICAL EQUIPMENT & SUPPLY CO., LTD.	+14.40%	5.47B
APT MEDICAL INC.	+32.74%	4.74B
GETINGE AB	-14.85%	4.89B
ASAHI INTECC CO., LTD.	-25.57%	3.7B
INARI MEDICAL, INC.	-23.06%	2.9B
NOVOCURE LIMITED	+55.06%	2.49B

Medical Equipment